FDA Approved: CINQAIR — Supplemental Application (Teva Respiratory, LLC)

View source ↗

Summary

FDA approved a supplemental application for CINQAIR (reslizumab) submitted by Teva Respiratory, LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Eosinophilic Asthma

Drugs mentioned

• CINQAIR (Reslizumab)

Snippet

SUPPL AP for CINQAIR (RESLIZUMAB)